| Summary: | Objective
To assess lower urinary tract symptoms and sexual function in premenopausal
women with metabolic syndrome (MetS).
Materials and Methods
A total of 34 premenopausal patients over 18 years of age with MetS and who
were admitted to our endocrinology clinic between September 2013 and April
2014 were included. Control group was consisted of 30 healthy controls chosen
from the staff of the hospital. The sexual function, lower urinary tract symptoms
and quality of life of the participants were evaluated by using Index of Female
Sexual Function (IFSF), Urogenital Distress Inventory (UDI-6), and Incontinence
Impact Questionnaire (IIQ-7), respectively. The scores of the patients were
statistically compared with those of controls.
Results
The mean ages of the patient and control groups were 40.50±5.12 years and
38.17±2.12 years, respectively (p=0.09). The mean IFSF-total and all of the IFSF
sub scales (except pain) in the patient group were significantly lower than those of
the control group. The mean UDI-6 score of the patients was significantly higher
than the controls (p=0.001). The mean IIQ-7 scores of the patients was higher than
controls, however this increase was not statistically significant (p=0.11).
Conclusion
These findings showed that MetS affected adversely the sexual function of
premenopausal women due to the fact that IFSF scores were found to be lower in
women with MetS as compared to healthy controls. Moreover, IFSF score under the
threshold values in patients showed that patients with MetS had sexual function
disorder. These lower urinary tract symptoms in the patients with MetS did not
affect the quality of life although the severity of lower urinary tract symptoms of
patients with MetS was significantly worse than that in control group.
|
|---|